ZBIOZenas BioPharma, Inc.
$26.87+11% 1Y
$26.87
$15.2052 weeks$43.17
Is the business good?
How good a business is ZBIO?
Zenas BioPharma, Inc. spent more than it took in: an operating loss of $476M on $1.0M of revenue, 12 months to Q2 2026.
$476M
Operating loss · on $1.0M of revenue · 12 months to Q2 2026
- Share count, year on year
- +51%
Share count, year on year · shareholders own a smaller slice than a year ago
| Year | Operating margin |
|---|---|
| FY2023 | −74% |
| FY2024 | −3278% |
| FY2025 | −3831% |
Details›
- Operating margin12 months to Q2 2026
- −47557%
- Net margin12 months to Q2 2026
- −48438%
- Free cash flow margin
- −22597%
- R&D as % of revenue
- 21347%
- Revenue, trailing twelve months
- $1.0M
- Free cash flow, trailing twelve months
- −$226M
- Net income, trailing twelve months
- −$484M
Margins, capital and share counts from the statements as filed with the SEC; cash conversion is operating cash flow over operating profit after tax.
On our screens:Most shorted stocks
Biotechnology
The closest names by size in the same industry